polyvalent antigen-klh conjugate vaccine
Biologicalexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Aug 1, 2008 (NCT00693342)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, active
Tumor antigens immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- polyvalent antigen-klh conjugate vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00857545 | Phase 2 | Jul 1, 2010 | Gynecologic Oncology Group, National Cancer Institute (NCI), NRG Oncology |
| NCT00693342 | Phase 3 | Aug 1, 2008 | Cornell University, Gynecologic Oncology Group, National Cancer Institute (NCI), Stanford University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gynecologic Oncology Group | Academic/Hospital | 2 | 2 | 2 | 2008 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2008 |
| Cornell University | Academic/Hospital | 1 | 0 | 1 | 2008 |
| NRG Oncology | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Stanford University | Academic/Hospital | 1 | 0 | 1 | 2008 |
5 organizations
Page 1 / 1